|
1
|
Sun Y, Nakamura T, Ohtsu Y, Kakehi M, Danno N, Shimizu H, Tanaka Y, Serelli-Lee V, Tanaka S, Okayama T, Suda Y, Moriya Y, Hanada T, Saito Y. Development and validation of qPCR methods for nucleic acid biomarkers as a drug development tool: points to consider. Bioanalysis 2023; 15:1069-1081. [PMID: 37584367 DOI: 10.4155/bio-2023-0071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/17/2023] Open
Abstract
Nucleic acid (NA) biomarkers play critical roles in drug development. However, the global regulatory guidelines for assessing quantification methods specific to NA biomarkers are limited. The validation of analytical methods is crucial for the use of biomarkers in clinical and post-marketing evaluations of drug efficacy and adverse reactions. Given that quantitative polymerase chain reaction (qPCR) and reverse transcription qPCR (RT-qPCR) methods are the gold standards for the quantification of NA biomarkers, the Biomarker Analytical Method Validation Study Group in Japan has discussed considerations and made recommendations for the development and validation of qPCR- and RT-qPCR-based analytical methods for endogenous NA biomarkers as drug development tools. This white paper aims to contribute to the global harmonization of NA biomarker assay validation.
Collapse
Affiliation(s)
- Yuchen Sun
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan
| | - Takahiro Nakamura
- Shin Nippon Biomedical Laboratories, Ltd, Kagoshima, 891-1394, Japan
| | | | - Masaaki Kakehi
- Takeda Pharmaceutical Company, Limited, Kanagawa, 251-8555, Japan
| | - Noriyuki Danno
- CMIC Pharma Science Co., Ltd, Yamanashi, 408-0044, Japan
| | | | - Yoichi Tanaka
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan
| | - Victoria Serelli-Lee
- Eli Lilly Japan KK, Hyogo, 651-0086, Japan
- Clinical evaluation sub-committee, Medicinal Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, Tokyo, 103-0023, Japan
| | - Seiji Tanaka
- ASKA Pharmaceutical Co., Ltd, Kanagawa, 251-8555, Japan
| | | | - Yusuke Suda
- Nippon Shinyaku Co., Ltd, Kyoto, 601-8550, Japan
| | - Yuu Moriya
- Takeda Pharmaceutical Company, Limited, Kanagawa, 251-8555, Japan
| | | | - Yoshiro Saito
- Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan
| |
Collapse
|
|
2
|
Ohtsu Y, Tanaka S, Igarashi H, Kakehi M, Mori T, Nakamura T, Ohashi R, Shimizu H, Yasuda Y, Okayama T, Kakuo H, Yokoi H, Horiuchi M, Katashima M, Nakamura R, Saito K, Saito Y. Analytical method validation for biomarkers as a drug development tool: points to consider. Bioanalysis 2021; 13:1379-89. [PMID: 34517750 DOI: 10.4155/bio-2021-0173] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Biomarkers are an important drug developmental tool. Assessment of quantitative analytical methods of biomarkers is not included in any regulatory documents in Japan. Use of biomarkers in clinical evaluations and supporting the post-marketing evaluation of drug efficacy and/or adverse reactions requires assessment and full validation of analytical methods for these biomarkers. The Biomarker Analytical Method Validation Study Group is a research group in Japan comprising industry and regulatory experts. Group members discussed and prepared this 'points to consider document' covering measurements of endogenous metabolites/peptides/proteins by ligand binding assays and chromatographic methods with or without mass spectrometry. We hope this document contributes to the global harmonization of biomarker assay validation.
Collapse
|